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Purpose. Radiation of extremity lesions, a key component of limb-sparing therapy, presents particular challenges, with signiﬁcant
risks of toxicities. We sought to explore the eﬃcacy of intraoperative radiation therapy (IORT) in the treatment of soft tissue sar-
comas of the extremities. Patients. Between 1995 and 2001, 17 patients received IORT for soft tissue sarcomas of the extremities.
Indications for IORT included recurrent tumors in a previously radiated ﬁeld or tumors adjacent to critical structures. Results.
Gross total resections were achieved in all 17 patients. Two patients experienced locoregional relapses, six patients recurred at
metastatic sites, and one patient died without recurrence. Thirty-six month estimates for locoregional control, disease free sur-
vival, and overall survival were 86%, 50%, and 78%, respectively. IORT was extremely well tolerated, with no toxicities referable
to IORT. Conclusions. For patients with soft tissue sarcomas of the extremities, IORT used as a boost to EBRT provides excellent
local control, with limited acute toxicities.
Copyright © 2006 Quy N. H. Tran et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Soft-tissue sarcomas (STSs) are relatively uncommon tu-
mors, representing 1% of adult and 7%–15% of pediatric
malignancies. They are a relatively heterogeneous group of
cancers that occur anywhere in the body, with 60% arising in
the extremities. There are at least 30 distinct histologic sub-
types of sarcomas that are further deﬁned by grade [1]. Such
diversity may present a clinical challenge, but for treatment
purposes, most soft-tissue sarcomas are grouped together.
Important prognostic factors, reﬂected in the newly revised
American Joint Committee on Cancer (AJCC) staging sys-
tem, include histologic grade, relationship to fascial planes,
and size of the primary tumor [2].
In the past, sarcomas arising in the extremities were fre-
quently treated with amputation, as limited resections re-
sulted in poor local control rates. In the past two decades,
limb-salvage approaches have drawn interest and attention,
particularly with the recent advent of multimodality therapy.
Treatment regimens that combine surgery, chemotherapy,
and radiation have allowed treating physicians to maintain
function without compromising disease control [3–10].
Limb-sparing therapy is therefore becoming the standard of
care [11, 12], with less than 10% of patients currently un-
dergoing amputation as primary therapy. With modern ap-
proaches, local control rates using limb-sparing techniques
exceed 75% for primary extremity lesions [11, 13].
Recently, intraoperative radiation therapy (IORT) has
been gaining favor. At our institution, IORT consists of a
single fraction of radiation, using electrons, administered at
the time of resection. Critical structures can be visualized
and manipulated to avoid dose-limiting toxicities to normal
structures, while a higher dose can be applied to residual tu-
mor volume and sites at high risk for microscopic disease.
Retrospective studies of various malignancies have suggested
that IORT may improve local control compared to standard
radiotherapy [14–18].
In conjunction with external beam radiation therapy
(EBRT), IORT contributes to higher total doses of radiation
to the tumorbed, while limiting long-term side eﬀects.Thus,2 Sarcoma
IORT allows for potentially higher local control rates while
reducing radiation toxicities [14–20]. Early clinical trials uti-
lizing IORT have reported favorable local control rates with
few patients experiencing IORT-related side eﬀects [21, 22].
Radiation has a well-established role in the treatment of
sarcomas, and we sought to enhance local control without
increasing radiation-induced toxicities by utilizing IORT as a
boost. Speciﬁcally, in this study, we sought to determine the
rates of local control, disease-free survival (DFS), overall sur-
vival (OS), and acute toxicities in patients who had received
limb-sparing therapy with IORT for sarcomas of the extrem-
ities at the University of California, San Francisco (UCSF).
PATIENTS
In this retrospective study, we report on 17 patients with
soft-tissue extremity sarcomas who were treated with limb-
sparing therapy, including IORT, between 1995 and 2001.
Details of surgery, radiation, chemotherapy, as well as
imaging studies and pathological diagnoses were acquired.
Follow-up duration was calculated from the date of IORT
untilthelastknownordocumentedvisitorthedateofdeath.
Patients were staged according to the AJCC staging system
for sarcomas that incorporates histologic grade, tumor size,
lymph node status, and metastases [2]. All patients in this
study had gross total resections (GTRs) with IORT at the
time of surgery.
Intraoperativeradiationtherapyboostsforextremitysar-
comas have been used at UCSF since 1995, but prior to 1997,
IORT was delivered in a suite in the Radiation Oncology De-
partment; patients were brought to the room at the time of
orwithin2daysofsurgery.Since1997,patientshavereceived
IORT at the time of primary resection within the operating
room,bymeansofadedicatedmobilelinearaccelerator[23].
Electron beams were delivered through lucite or aluminum
cones 3–10cm in interior diameter. Beam energies ranging
from 4MeV to 12MeV were used to limit the depth of the
absorbed dose to the areas at risk, while encompassing the
targetvolumeswithinthe90%isodoseline.Themediandose
was 12.5Gy (range 12–15Gy) delivered in a single fraction.
One to twoseparate IORTﬁelds were usedto coverthe entire
target volume. The surgeon and radiation oncologist made
ﬁnal decisions at the time of surgery regarding the areas at
risk for microscopic residual disease. The target volume was
the tumor bed as determined by preoperative imaging, op-
erative ﬁndings, and, when necessary, intraoperative frozen
sections. Shielding of normal tissues not at risk for disease
was accomplished by physical manipulation to exclude them
from the radiation ﬁeld, or by lead sheets.
The indications for IORT included recurrent tumors
within a previously radiated ﬁeld, or tumors where mar-
gin status was in question, due to close proximity of criti-
cal structures, such as nerves or vessels. Patients with tumors
close to critical structures were treated with IORT as a boost,
rather than preoperative radiation, because of the increased
wound complications seen with preoperative radiation ther-
apy [24]. This study was approved by the Committee on Hu-
man Research, University of California, San Francisco, Insti-
tutional Review Board.
Table 1: Patient characteristics and treatment details.
Variables Number
Number of patients 17
Median age (range), years 37 (8–86)
Female : male 8 : 9
Primary tumor location
Upper distal extremity 4
Upper proximal extremity 1
Lower distal extremity 3
Lower proximal extremity 9
Histology
Synovial sarcoma 6
Malignant ﬁbrous histiocytoma 4
Alveolar rhabdomyosarcoma 2
Ewing sarcoma 2
Angiomyxoma 1
Angiosarcoma 1
Leiomyosarcoma 1
Stage (AJCC)
I1
II 6
III 7
IV 3
EBRT, yes : no 13 : 4
Chemotherapy, yes : no 10 : 7
Surgical margins,∗ p o s i t i v e:n e g a t i v e 6:1 1
Disease status at time of IORT
Primary 16
Recurrent 1
Abbreviations: AJCC = American Joint Committee on Cancer. IORT =
intraoperative radiation therapy. EBRT = external beam radiation therapy.
∗A positive surgical margin was deﬁned as a margin less than 1mm.
METHODS
Descriptive statistics were used to characterize these patients
with extremity sarcomas. A single group of 17 patients was
analyzed, and therefore no statistical comparisons of subsets
were performed. Between 1995 and 2001, 61 patients total
weretreatedwithradiationforsoft-tissuesarcomasoftheex-
tremities at our institution. The Kaplan-Meier product limit
method was used to estimate the probabilities of local con-
t r o l ,D F S ,a n dO S .S u r v i v a lw a sm e a s u r e df r o mt h ed a t eo f
IORT treatment until the date of death or date of last con-
tact, if the patient was still alive. DFS was measured from the
date of IORT treatment until the date of failure or death or
date of last contact if the patient was last known to be disease
free. Local failure was deﬁned as documented disease within
the radiation ﬁeld or in the primary site, and regional fail-
ure was deﬁned as disease recurrence directly adjacent to the
original site of disease or in adjacent lymph node groups.
RESULTS
Patient characteristics are summarized in Table 1.H i g h -
grade lesions were noted in all stage II patients, while theQuy N. H. Tran et al 3
Table 2: Patient outcome and follow-up.
Age Histology Location Presenting
stage
Failure IORT Site of
EBRT
Surgical
margins
Site of ﬁrst Status FU
(months) Pt at of of in IORT dose progression at last
Dx primary primary ﬁeld (Gy) after IORT FU
1 86 Malignant ﬁbrous histiocytoma Buttock III Yes 12.5 Buttock − Buttock Dead 3
2 68 Malignant ﬁbrous histiocytoma Thigh III No 12 Thigh − Acetabulum AWD 23
3 18 Synovial sarcoma Knee II No 15 Knee − Lungs AWD 15
4 39 Synovial sarcoma, recurrent Thigh IV No 15 Thigh − Lungs AWD 17
5 9 Alveolar rhabdomyosarcoma Calf III No 12 None − RP LN AWD 53
6 54 Angiosarcoma Thigh II No 15 Thigh + Lungs AWD 24
7 9 Ewing sarcoma Prox add IV No 12.5 Prox add + Lungs Dead 5
8 18 Ewing sarcoma Buttock IV No 12.5 Buttock + Lungs Dead 41
9 8 Monomorphic synovial sarcoma Forearm II No 12.5 Forearm + None NED 39
10 76 Malignant ﬁbrous histiocytoma Groin III No 15 Groin/add − None NED 15
11 59 Malignant ﬁbrous histiocytoma Forearm III No 12.5 Forearm + None NED 32
12 31 Angiomyxoma Thigh I No 15 None − None NED 37
13 20 Alveolar rhabdomyosarcoma Forearm III No 12.5 Forearm − None NED 17
14 21 Synovial sarcoma Shoulder II No 12.5 None − None NED 11
15 46 Synovial sarcoma Hand III No 12.5 Hand + None NED 34
16 37 Synovial sarcoma Popl fossa II No 12.5 Popl fossa − None NED 25
17 38 Leiomyosarcoma Groin II No 12.5 None − None Dead 23
Abbreviations:P t= patient number; Dx = diagnosis; IORT = intraoperative radiation therapy; EBRT = external beam radiation therapy; FU = follow-up;
prox = proximal; add = adductor; popl = popliteal; RP = retroperitoneal; LN = lymph node; AWD = alive with disease; NED = no evidence of disease.
Note: Patients 1–2 failed locoregionally and patients 3–8 failed distantly.
single stage I patient had a low-grade lesion. Six stage III pa-
tients and one stage IV patient had high-grade lesions. No
grade was noted on pathology reports of one stage III patient
and two stage IV patients. All patients had GTRs, but 8 pa-
tients had previous attempts at resections. Following GTRs,
6 patients had positive surgical margins. Ten of 17 patients
received chemotherapy as part of their initial treatment. Al-
though it is our institutional policy to administer neoadju-
vant chemotherapy for most high-grade sarcomas in adults
(usually a doxorubicin- or ifosfamide-based regimen), the
remaining patients did not receive chemotherapy due to ei-
ther low-grade histology, advanced age, or poor Karnofsky
performance status.
IORT was administered at the time of original presenta-
tion in 16 patients and at the time of tumor recurrence in 1
patient. Thirteen of 17 patients received postoperative exter-
nal beam radiation therapy, with a median dose of 50.3Gy
(range 43.2–61.2Gy) and a median number of 26 fractions
(range 20–33 fractions). Treatment was completed within
a median time of 76 days (range 62–118 days) from date
of IORT. Although the intent of the study was to adminis-
ter IORT as a boost to EBRT, four patients did not receive
EBRT; one patient received brachytherapy, two patients de-
clined EBRT, and one patient died of unrelated causes be-
fore receiving EBRT. The patient who received brachyther-
apy in addition to IORT had an unusual dumbbell-shaped
tumor and his treatment diﬀered somewhat from the stan-
dard approach at our institution. The superﬁcial portion of
the tumor was completely resected and received IORT; the
deep portion of the tumor proved unresectable at the time of
surgery and was therefore treated with brachytherapy.
Patient follow-up and clinical outcomes are summarized
in Table 2. Patients 1–8 experienced disease recurrence. Pa-
tient 1 failed within the IORT ﬁeld, but died of metastatic
disease 3 months after surgery and IORT. Patient 2 failed ad-
jacent to the IORT ﬁeld and is currently alive with disease
(AWD). Patients 3–8 failed at distant sites, with ﬁve patients
developinglungmetastasesandonepatienthavingretroperi-
toneallymphnodesinvolvement.Noneofthe6patientswith
positive surgical margins had a local recurrence. Three pa-
tients presented with metastatic disease at the time of diag-
nosis (patients 4, 7, and 8). Patient 4 is AWD 17 months after
diagnosis, and patients 7 and 8 died of metastatic disease, 5
and 41 months after diagnosis, respectively, both with con-
trol of local disease sites.
Median follow-up for all patients was 23 months (range
3–53 months), with median follow-up for surviving patients
of 24 months (range 11–53 months). Median OS was 41
months but only 1 patient has been followed beyond the me-
dian time indicating that this estimate may reﬂect censoring
(Figure 1). Eight patients are alive with no evidence of dis-
ease (NED). One patient died of unrelated causes prior to
initiation of EBRT, while still NED. Median DFS was 23.4
months, resulting from 2 locoregional failures, 6 distant fail-
ures, and 1 death without recurrence (Figure 2). Two of 17
patients failed locoregionally at 2 and 11 months after IORT
(Figure 3). The median has not been reached for locore-
gional control, but locoregional control remains at 86% as4 Sarcoma
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Figure 1: Overall survival. Kaplan-Meier probability estimates.
Four of the 17 patients died.
36 24 12 0
Months from IORT
0
0.25
0.5
0.75
1
C
u
m
u
l
a
t
i
v
e
p
r
o
p
o
r
t
i
o
n
Figure 2: Disease-free survival. Kaplan-Meier probability esti-
mates. Two patients failed locoregionally, 6 patients failed distantly,
and 1 patient died without recurrence.
of 11 months after IORT with the longest failure-free obser-
vation being 44 months. Thirty-six month estimates for lo-
coregional control, DFS, and OS, were 86%, 50%, and 78%,
respectively.
Of the 17 patients, ﬁve were 18 years of age or younger
at diagnosis. Three of the ﬁve pediatric patients had posi-
tive surgical margins following GTRs. None of the pediatric
patients recurred locally. Patient 5 developed retroperitoneal
lymph node metastases and is currently AWD. Of patients 3,
7,and8whodevelopedlungmetastases,twohavediedofdis-
ease and one is AWD. Patient 9, who presented with localized
synovial sarcoma of the forearm, is alive, without evidence of
disease, 39 months after resection with IORT.
IORT was extremely well tolerated in our cohort. Al-
thoughfollow-upwasnotlongenoughtoassesslatetoxicities
associated with IORT, there were no acute toxicities noted.
Of the 13 patients who received subsequent EBRT, six expe-
rienced mild to moderate erythema, one experienced pain,
oneblistering,andthreepatientsexperienceddesquamation.
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Figure 3:Locoregionalcontrol.Twoofthe17patientsfailedlocore-
gionally.
DISCUSSION
STSs are characterized by high local recurrence rates follow-
ing surgical excision alone. While the addition of radiation
therapyhassuccessfullyimprovedlocalcontrol,multimodal-
ity therapy for extremity sarcomas has sustained local con-
trol rates while limiting the need for amputations and mor-
bid surgical procedures. The beneﬁts of radiation therapy
f o rS T S sh a v eb e e nd o c u m e n t e di nr e t r o s p e c t i v ea sw e l la s
prospective, randomized trials [13, 24]. However, delivering
adequate doses of EBRT to extremity lesions can present par-
ticular challenges.
Complications including wound breakdown, skin graft
failure, and ﬂap necrosis occur in approximately 17% of pa-
tients receiving postoperative EBRT and 35% of patients re-
ceiving preoperative EBRT [24–26]. In addition, extremities
are particularly susceptible to long-term sequelae of ﬁbrosis
and edema resulting from EBRT administered in the preop-
erative or postoperative setting [24]. We therefore sought to
enhance the beneﬁts of EBRT, while reducing associated tox-
icities by utilizing an IORT boost for patients with extremity
STSs.
In the treatment of sarcomas, IORT has generally been
used for tumors arising in the abdomen and pelvis. In a
prospective trial of retroperitoneal sarcomas, 35 patients
were randomized between 50–55Gy of EBRT alone and 20
Gy IORT plus 35–40Gy EBRT. Although initial analyses
demonstrated less toxicity in the IORT arm without im-
provement in DFS or OS [27], an updated analysis revealed
a signiﬁcant reduction in locoregional recurrences in the
group receiving IORT [28]. This group also had a lower in-
cidence of disabling enteritis, although peripheral neuropa-
thy was more common in the IORT group than among con-
trols receiving high-dose EBRT withoutIORT. A more recent
phase I trial of patients with localized retroperitoneal sarco-
mas demonstrated that IORT was feasible and was success-
fully administered [22].
Few studies address local control, tissue tolerance, and
eﬀectiveness of IORT in the treatment of extremity STSs.Quy N. H. Tran et al 5
Azinovic et al reported a study of 45 patients with extremity
STSstreatedwithIORT[29].Theyreported5-yearlocalcon-
trol rates of 88% in patients with negative surgical margins
and 57% in patients with positive surgical margins. Five pa-
tients developed neuropathies following treatment. Dubois
et al published a series of 31 patients with STSs, of which 18
patients had extremity STSs treated with IORT [30]. They
reported 4 local failures among the 31 patients but no local
failures in patients with extremity or trunk STSs.
V a nK a m p e ne ta lt r e a t e d6 8e x t r e m i t yS T Sp a t i e n t sw i t h
IORT and reported a 5-year OS of 70% and local control rate
of 88% [31]. Analyzing a subset of 58 patients for late se-
quelae using the LENT-SOMA scoring system for soft-tissue
ﬁbrosis, they noted that 4 patients had Grade 1-, 2 patients
had Grade 2-, 5 patients had Grade 3-, and 1 patient had
Grade 4-ﬁbrosis. Lehnert et al reported a series of 251 pa-
tients with soft-tissue sarcomas; 131 patients had extremity
STSs, of which 55 received IORT [32]. Five-year OS and local
control rates were 78% and 83%, respectively, with a surgical
complication rate of 25%. Although treatment assignment
to IORT was nonrandom, it is interesting to note that among
patients who did not receive IORT, the 5-year OS rate was
57% and the 5-year local control rate was 68%, reﬂecting a
trendtowarddecreasedmorbidityandmortalitywiththeuse
of IORT.
Given these preliminary, yet promising experiences of
IORT in the treatment of STSs, we sought to explore our in-
stitutional experience using IORT as a component of mul-
timodality therapy for extremity STSs. Of these patients, 17
had extremity STSs that were treated with IORT and the lo-
coregional control was 86%, a ﬁgure comparable to prior
published results. There were no locoregional recurrences
in the 6 patients with positive surgical margins. Previous
studies have shown a lower local regional control rate in
patients with positive surgical margins [1, 29], but our re-
sults suggest that IORT as a boost could represent an im-
provement in the management of these patients. In addi-
tion, EBRT administered to the extremities poses particu-
lar challenges with signiﬁcant risks of ﬁbrosis, edema, and
compromised function. IORT was well tolerated in our co-
hort with no acute toxicities, but follow-up was not long
enough to comment on late toxicities such as neuropathy
or ﬁbrosis. Thirteen patients experienced various degrees of
dermal toxicities following EBRT, none of unexpected sever-
ity.
Although we present encouraging results, the report is
limited by the retrospective nature of the study. It includes a
small number of patients, diverse histologies, various stages
of presentation, and multiple treatment techniques. How-
ever, given these hopeful results, we anticipate a future
prospective study that will address these limitations. In such
a future study, we hope to demonstrate the utility of IORT
as a boost to EBRT and a means of providing excellent lo-
cal control with limited acute toxicity. It is our institution’s
policy to use IORT as a boost to EBRT for all patients with
soft-tissue sarcomas of the extremity in whom proximity to
critical structures such as neurovascular bundles precludes
complete resection with adequate, negative margins.
ACKNOWLEDGMENT
ThisworkwassupportedinpartbyanawardfromtheAmer-
ican Society of Clinical Oncology (DAH-K) and the Nancy
and Stephen Grand Philanthropic Fund (D.A.H-K).
REFERENCES
[1] PistersPWT,PollockRE.Stagingandprognosticfactorsinsoft
tissue sarcoma. Seminars in Radiation Oncology. 1999;9(4):
307–314.
[2] GreeneFL,PageDL,FlemingID,FritzA,BalchCM,eds.AJCC
Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
[3] Benjamin RS. Evidence for using adjuvant chemotherapy as
standard treatment of soft tissue sarcoma. Seminars in Radia-
tion Oncology. 1999;9(4):349–351.
[4] Heyn R, Beltangady M, Hays D, et al. Results of intensive
therapy in children with localized alveolar extremity rhab-
domyosarcoma: a report from the Intergroup Rhabdomyosar-
coma Study. Journal of Clinical Oncology. 1989;7(2):200–207.
[5] Hintz BL, Charyulu KK, Miller WE, Sudarsanam A. Adjuvant
role of radiation in soft tissue sarcoma in adults. Journal of
Surgical Oncology. 1977;9(4):329–338.
[6] Kinsella TJ, Lichter AS, Miser J, Gerber L, Glatstein E. Lo-
cal treatment of Ewing’s sarcoma: radiation therapy versus
surgery. Cancer Treatment Reports. 1984;68(5):695–701.
[ 7 ]L e i b e lS A ,T r a n b a u g hR F ,W a r aW M ,B e c k s t e a dJ H ,B o v i l l
EG, Phillips TL. Soft tissue sarcomas of the extremities: sur-
vival and patterns of failure with conservative surgery and
postoperative irradiation compared to surgery alone. Cancer.
1982;50(6):1076–1083.
[8] Pisters PWT. Combined modality treatment of extremity soft
tissue sarcomas. Annals of Surgical Oncology. 1998;5(5):464–
472.
[9] Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of
soft-tissue sarcomas of the extremities: prospective random-
ized evaluations of (1) limb-sparing surgery plus radiation
therapy compared with amputation and (2) the role of adju-
vant chemotherapy. Annals of Surgery. 1982;196(3):305–315.
[10] Sarcoma Meta-analysis Collaboration. Adjuvant chemother-
apyforlocalizedresectablesoft-tissuesarcomaofadults:meta-
analysis of individual data. Lancet. 1997;350(9092):1647–
1654.
[11] O’Sullivan B, Wylie J, Catton C, et al. The local manage-
ment of soft tissue sarcoma. Seminars in Radiation Oncology.
1999;9(4):328–348.
[12] Potter DA, Kinsella T, Glatstein E, et al. High-grade soft tissue
sarcomas of the extremities. Cancer. 1986;58(1):190–205.
[13] Yang JC, Chang AE, Baker AR, et al. Randomized prospective
study of the beneﬁt of adjuvant radiation therapy in the treat-
ment of soft tissue sarcomas of the extremity. Journal of Clini-
cal Oncology. 1998;16(1):197–203.
[14] Abe M, Shibamoto Y. The usefulness of intraoperative radi-
ation therapy in the treatment of pelvic recurrence of cervi-
cal cancer. International Journal of Radiation Oncology Biology
Physics. 1996;34(2):513–514.
[15] Abe M, Takahashi M. Intraoperative radiotherapy: the Japa-
nese experience. International Journal of Radiation Oncology
Biology Physics. 1981;7(7):863–868.
[16] Hanks GE, Lanciano RM. Intraoperative radiation therapy:
cut bait or keep on ﬁshing? International Journal of Radiation
Oncology, Biology, Physics. 1996;34(2):515–517.6 Sarcoma
[17] Kim HK, Jessup JM, Beard CJ, et al. Locally advanced rectal
carcinoma: pelvic control and morbidity following preopera-
tive radiation therapy, resection, and intraoperative radiation
therapy. International Journal of Radiation Oncology, Biology,
Physics. 1997;38(4):777–783.
[18] Matsumoto K, Kakizoe T, Mikuriya S, Tanaka T, Kondo I,
Umegaki Y. Clinical evaluation of intraoperative radiotherapy
for carcinoma of the urinary bladder. Cancer. 1981;47(3):509–
513.
[19] Gunderson LL, Nagorney DM, McIlrath DC, et al. External
beam and intraoperative electron irradiation for locally ad-
vanced soft tissue sarcomas. International Journal of Radiation
Oncology, Biology, Physics. 1993;25(4):647–656.
[20] Valentini V, Balducci M, Tortoreto F, Moranti AG, De Giorgi
U, Fiorentini G. Intraoperative radiotherapy: current think-
ing. European Journal of Surgical Oncology. 2002;28(2):180–
185.
[21] Cromack DT, Maher MM, Hoekstra H, Kinsella TJ, Sinde-
lar WF. Are complications in intraoperative radiation ther-
apy more frequent than in conventional treatment? Archives
of Surgery. 1989;124(2):229–234.
[22] Pisters PWT, Ballo MT, Fenstermacher MJ, et al. Phase I trial
ofpreoperativeconcurrentdoxorubicinandradiationtherapy,
surgical resection, and intraoperative electron-beam radiation
therapy for patients with localized retroperitoneal sarcoma.
Journal of clinical oncology. 2003;21(16):3092–3097.
[23] Meurk ML, Goer DA, Spalek G, Cook T. The Mobetron: a new
concept for IORT. Frontiers of Radiation Therapy and Oncol-
ogy. 1997;31:65–70.
[24] O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus
postoperativeradiotherapyinsoft-tissuesarcomaofthelimbs:
a randomised trial. Lancet. 2002;359(9325):2235–2241.
[25] Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft
tissue sarcomas: preoperative versus postoperative radiother-
apy. Journal of Surgical Oncology. 1996;61(2):90–99.
[26] SpiererMM,AlektiarKM,ZelefskyMJ,BrennanMF,Cordiero
PG. Tolerance of tissue transfers to adjuvant radiation ther-
apy in primary soft tissue sarcoma of the extremity. In-
ternational Journal of Radiation Oncology, Biology, Physics.
2003;56(4):1112–1116.
[27] Kinsella TJ, Sindelar WF, Lack E, Glatstein E, Rosenberg SA.
Preliminary results of a randomized study of adjuvant radia-
tion therapy in resectable adult retroperitoneal soft tissue sar-
comas. Journal of Clinical Oncology. 1988;6(1):18–25.
[28] Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative ra-
diotherapy in retroperitoneal sarcomas. Final results of a
prospective, randomized, clinical trial. Archives of Surgery.
1993;128(4):402–410.
[29] Azinovic I, Monge RM, Aristu JJ, et al. Intraoperative radio-
therapy electron boost followed by moderate doses of external
beam radiotherapy in resected soft-tissue sarcoma of the ex-
tremities. Radiotherapy and Oncology. 2003;67(3):331–337.
[30] Dubois JB, Debrigode C, Hay M, et al. Intra-operative radio-
therapy in soft tissue sarcomas. Radiotherapy and Oncology.
1995;34(2):160–163.
[31] van Kampen M, Eble MJ, Lehnert T, et al. Correlation of in-
traoperatively irradiated volume and ﬁbrosis in patients with
soft-tissue sarcoma of the extremities. International Journal of
Radiation Oncology Biology Physics. 2001;51(1):94–99.
[32] Lehnert T, Schwarzbach M, Willeke F, et al. Intraoperative ra-
diotherapy for primary and locally recurrent soft tissue sar-
coma: morbidity and long-term prognosis. European Journal
of Surgical Oncology. 2000;26(suppl A):S21–S24.